Analysts expect Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) to announce earnings of ($0.14) per share for the current quarter, Zacks reports. Three analysts have provided estimates for Infinity Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.14) and the highest estimate coming in at ($0.13). Infinity Pharmaceuticals posted earnings of ($0.19) per share in the same quarter last year, which would suggest a positive year-over-year growth rate of 26.3%. The business is scheduled to report its next earnings results on Monday, May 10th.

According to Zacks, analysts expect that Infinity Pharmaceuticals will report full year earnings of ($0.55) per share for the current financial year, with EPS estimates ranging from ($0.62) to ($0.52). For the next financial year, analysts forecast that the firm will report earnings of ($0.57) per share, with EPS estimates ranging from ($0.66) to ($0.47). Zacks’ EPS averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Infinity Pharmaceuticals.

Infinity Pharmaceuticals (NASDAQ:INFI) last issued its quarterly earnings results on Monday, March 15th. The biotechnology company reported ($0.16) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.16). Infinity Pharmaceuticals had a negative return on equity of 1,358.77% and a negative net margin of 2,592.65%.

A number of research firms have issued reports on INFI. Piper Sandler began coverage on Infinity Pharmaceuticals in a research report on Thursday, February 25th. They issued an “overweight” rating and a $7.00 target price for the company. Truist Securities began coverage on Infinity Pharmaceuticals in a research report on Wednesday, March 24th. They issued a “buy” rating and a $12.00 target price for the company. Oppenheimer raised their target price on Infinity Pharmaceuticals from $5.50 to $9.00 and gave the stock an “outperform” rating in a research report on Thursday, February 11th. B. Riley decreased their target price on Infinity Pharmaceuticals from $8.00 to $7.00 and set a “buy” rating for the company in a research report on Tuesday, March 23rd. Finally, Wells Fargo & Company raised their target price on Infinity Pharmaceuticals from $2.00 to $4.00 and gave the stock an “equal weight” rating in a research report on Tuesday, March 23rd. Two analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $8.31.

In related news, major shareholder Bvf Partners L. P/Il sold 5,848,520 shares of the business’s stock in a transaction dated Friday, January 22nd. The stock was sold at an average price of $4.14, for a total transaction of $24,212,872.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 13.77% of the stock is currently owned by insiders.

Institutional investors have recently bought and sold shares of the stock. Renaissance Technologies LLC grew its position in Infinity Pharmaceuticals by 24.0% during the fourth quarter. Renaissance Technologies LLC now owns 2,215,974 shares of the biotechnology company’s stock worth $4,698,000 after buying an additional 429,041 shares in the last quarter. Morgan Stanley grew its position in Infinity Pharmaceuticals by 268.9% during the third quarter. Morgan Stanley now owns 35,251 shares of the biotechnology company’s stock worth $41,000 after buying an additional 25,695 shares in the last quarter. BlackRock Inc. grew its position in Infinity Pharmaceuticals by 0.6% during the fourth quarter. BlackRock Inc. now owns 976,446 shares of the biotechnology company’s stock worth $2,071,000 after buying an additional 5,748 shares in the last quarter. Callan Capital LLC purchased a new position in Infinity Pharmaceuticals during the fourth quarter worth about $155,000. Finally, JPMorgan Chase & Co. grew its position in Infinity Pharmaceuticals by 165,024.0% during the fourth quarter. JPMorgan Chase & Co. now owns 41,281 shares of the biotechnology company’s stock worth $88,000 after buying an additional 41,256 shares in the last quarter. Institutional investors and hedge funds own 46.66% of the company’s stock.

Infinity Pharmaceuticals stock traded up $0.17 during mid-day trading on Friday, reaching $3.51. 35,600 shares of the company’s stock were exchanged, compared to its average volume of 3,897,280. The business’s fifty day simple moving average is $3.27 and its 200 day simple moving average is $2.43. Infinity Pharmaceuticals has a one year low of $0.78 and a one year high of $5.98. The firm has a market capitalization of $311.13 million, a PE ratio of -4.70 and a beta of 2.40.

About Infinity Pharmaceuticals

Infinity Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing novel medicines for people with cancer. It offers IPI-549, an orally administered, clinical-stage, immuno-oncology product candidate that selectively inhibits the enzyme phosphoinositide-3-kinase-gamma Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma), which is in Phase 1/1b clinical study.

Read More: What is channel trading?

Get a free copy of the Zacks research report on Infinity Pharmaceuticals (INFI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Infinity Pharmaceuticals (NASDAQ:INFI)

Receive News & Ratings for Infinity Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Infinity Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.